properties can lead to variations in safety and clinical efficacy for the treatment of autoimmune conditions. It has been noted that up to one‐third of RA patients do not respond to anti‐TNF therapy due to genetic factors.21
Table 3.5 Examples of cytokine drugs and diseases treated.
Source: Food and Drug Administration (FDA) DailyMed.17
| Type of cytokine | Drug name | Manufacturer | Disease(s) treated (per FDA labeling) |
|---|---|---|---|
| Interferon | Actimmune® (interferon gamma‐1b) | Horizon Pharma Inc. | Chronic granulomatous disease; Severe, malignant osteopetrosis |
| Avonex® (interferon beta‐1a) | Biogen Inc. | Multiple sclerosis | |
| Betaseron® (interferon beta‐1b) | Bayer HealthCare | Multiple sclerosis | |
| Extavia® (interferon beta‐1b) | Novartis | Multiple sclerosis | |
| Intron A® (interferon alfa‐2b) | Merck Sharp & Dohme Corp | Hairy cell leukemia; Malignant melanoma; Follicular lymphoma; Condylomata acuminate; AIDS‐related Kaposi's sarcoma; Chronic hepatitis C; Chronic hepatitis B | |
| Interleukin | Actemra® (tocilizumab) | Genentech | Rheumatoid arthritis; Giant cell arteritis; Polyarticular juvenile idiopathic arthritis; Systemic juvenile idiopathic arthritis; Cytokine release syndrome |
| Cosentyx® (secukinumab) | Novartis | Plaque psoriasis; Psoriatic arthritis; Ankylosing spondylitis | |
| Dupixent® (dupilumab) | Sanofi‐Aventis | Atopic dermatitis; Asthma | |
| Kineret® (anakinra) | Swedish Orphan Biovitrum AB | Rheumatoid arthritis; Cryopyrin‐associated periodic syndromes | |
| Nucala® (mepolizumab) | GlaxoSmithKline | Severe asthma | |
| Zinbryta® (daclizumab) | Abbvie | Multiple sclerosis | |
| Tumor necrosis factor | Enbrel® (etanercept) | Amgen | Rheumatoid arthritis; Polyarticular juvenile idiopathic arthritis; Psoriatic arthritis; Ankylosing spondylitis; Plaque psoriasis |
| Humira® (adalimumab) | Abbvie | Rheumatoid arthritis; Juvenile idiopathic arthritis; Psoriatic arthritis; Ankylosing spondylitis; Plaque psoriasis; Crohn's disease; Pediatric Crohn's disease; Ulcerative colitis; Hidradenitis suppurativa; Uveitis | |
| Remicade® (infliximab) | Janssen Biotech | Crohn's disease; Pediatric Crohn's disease; Ulcerative colitis; Pediatric ulcerative colitis; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Plaque psoriasis | |
| Erythropoietin | Aranesp® (darbepoetin alfa) | Amgen | Anemia due to chronic kidney disease; Anemia due to chemotherapy in patients with cancer |
| Procrit® (erythropoietin) | Janssen | Anemia due to chronic kidney disease; Anemia due to zidovudine in patients with HIV‐infection; Anemia due to chemotherapy in patients with cancer; Reduction of allogenic red blood cell transfusions in patients undergoing elective, noncardiac surgery; Nonvascular surgery | |
| Colony stimulating growth factor | Neulasta® (pegfilgrastim) | Amgen | Patients with cancer receiving myelosuppressive chemotherapy; Patients with hematopoietic subsyndrome of acute radiation syndrome |
| Vascular endothelial growth factor | Avastin® (bevacizumab) | Genentech | Metastatic colorectal cancer |
3.2.9 Hormones
Biological drugs target a diverse array of hormone‐mediated systems. Hormones are intercellular messengers that can be categorized as steroids, polypeptides, or amino acid derivatives. Steroids include estrogens, androgens, and mineral corticoids. Polypeptides include insulin and endorphins, and amino acid derivatives can include epinephrine, norepinephrine, adrenaline, and noradrenaline.2 The development of a therapeutic insulin has been one of the most important pharmaceutical endeavors to date; a timeline provided in Table 3.6 demonstrates how insulin's discovery and manufacturing have shaped modern medicine and drug development.
One of the most impactful scientific breakthroughs in the development of insulin was the ability to produce human insulin on an industrial scale using rDNA techniques. Prior to this, in the 1970s, diabetic patients were injected with insulins derived from animal sources. Mass‐produced human insulin made from rDNA could be produced uniformly and carried the potential to alleviate shortages inherent in animal‐insulin supply. While insulin was the first drug produced using recombinant technology, the capability extends to most of the biological drugs developed to date and continues to progress biotechnological and pharmaceutical sciences today.
Table 3.6 Insulin: timeline of discovery and manufacture.
Source: Adapted from https://www.diabetes.co.uk/insulin/history‐of‐insulin.html.22
| 1869 – The Islets of Langerhans cells are discovered in the pancreas |
| 1901 – The Islets of Langerhans are identified as cells that produce insulin |
| 1916 – Pancreas extract is found to lower blood sugar when given to diabetic dogs |
| 1921 – Studies show that pancreas removal in dogs results in the symptoms of diabetes; cow pancreas extract demonstrated improvement in the dog's health when given and was termed “insulin” |
|
1922 – A young boy with type 1 diabetes lives for 13 years beyond typical mortality as the first recipient of medical insulin; Eli Lilly becomes the first insulin manufacturer
|